GV1001 Treatment Shows Promise for Moderate to Severe Alzheimer’s

GV1001 Treatment Shows Promise for Moderate to Severe Alzheimer’s

291599

GV1001 Treatment Shows Promise for Moderate to Severe Alzheimer’s

Six months of treatment with GemVax & KAEL’s investigational GV1001 provided benefits in the cognition and daily life activities of adults with moderate to severe Alzheimer’s disease, who take Aricept (donepezil) for dementia, according to data from a Phase 2 clinical trial. The results were published in an article, “Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial,” in the journal…

You must be logged in to read/download the full post.